Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Resverlogix Corp T.RVX

Alternate Symbol(s):  RVXCF

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.


TSX:RVX - Post by User

Bullboard Posts
Comment by toinv261on Feb 13, 2018 10:29am
171 Views
Post# 27550256

RE:RE:RE:RE:RE:HOPE THIS DOES NOT HAPPEN TO RVX

RE:RE:RE:RE:RE:HOPE THIS DOES NOT HAPPEN TO RVXHi GV. Good points. Thanks.

Yes, I've been critical of Don on Agora and I have had my knuckles smacked over there and I told Kelsee I totally agree with the warning. I've made my point and I will try not to harp on Don unless conditions change in a direction that bothers me e.g. another deal that does not generate much needed capital.

I think fouremm explressed the frustrations very well on Agora.
Source - fouremm, Feb 12th, 2018, 7:15 p.m. – on Agoracom
  • Kelsee, firstly thank you for the great job you and the others do managing this hub. While I agree that things will unfold to the company’s timeline and not ours I think management needs to do a much better job at accurately communicating those timelines and managing investors expectations. I have trouble remembering the last time we were told something was in the works and it actually happened in the timeframe as per guidance given. I understand and feel the frustration of others.  I think everyone here understands the risks inherent to biotech. Good management should provide good execution, clear communication and in general be managing to keep the risks involved down to the science. Management at RVX has rarely achieved this in my opinion.
GV, you seemed to suggest that I may not really be long on the stock (hence implying I may be trying to hurt the value of the stock). I'm long, pure and simple on the science. Here is my history. I bought in during April 2010 and paid in the $6 plus range. I also dollar cost averaged down after this period. In 2013 I was thrilled about spinco and I hold thousands of shares of Zenith (and by the way I am not happy with Don's performance at Zenith. One CEO can't do it all. This issue was raised to Don at the Q & A and apparently he thinks all is OK.). In June of 2013 I held my shares and they were trading around $3.50+. Then we had the ASSURE top lines and the share dropped down to around $0.20 for a period. I did not sell a share. I wish I would have been a buyer then. Post ASSURE we have seen nothing but positive results and NO negatives on the science side. I am long!

In terms of posting my purpose in posting not to hype the stock. The reason I post is to understand. I put out my ideas and I expect to be challenged and criticised and thus gain further understanding. 

Also, I am not a group think person and I will never roll with the pack unless I feel there is real substance in the group's thinking. I'm currently researching a case study in the massive failure of Target in Canada (costing them over $1 billion) and one of the dominant themes was group think throughout the organization.

Finally I view RVX as a grossly undervalued scientific gem. One simple calculus is the Beacon NPV of $8+ vs. the market at ~$1.80. Is the gap due to doubts about the science? Perhaps. However, we are now seeing independent scientists experimenting with apabetalone and generating positive findings in retinal, MD, HIV, etc.

I'll leave it to that. I do have another analogy about Don but I will not state it. Enough has been said.

Thanks GV for your post. You got me thinking. All the best!
GLTA
Toinv

Bullboard Posts